Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Initial treatment

Clinical criteria:

• The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication,

AND

• The condition must be non-squamous type non-small cell lung cancer (NSCLC) or not otherwise specified type NSCLC,

AND

• Patient must have a WHO performance status of 2 or less,

AND

• Patient must have evidence of an anaplastic lymphoma kinase (ALK) gene rearrangement in tumour material, defined as either: (i) 15% (or greater) positive cells by fluorescence in situ hybridisation (FISH) testing, (ii) positive next generation sequencing (NGS) testing.

Treatment criteria:

• Must be treated by a medical practitioner.

Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Treatment Phase: Continuing treatment

Clinical criteria:

• The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication,

AND

• Patient must have previously received PBS-subsidised treatment with this drug for this condition,

AND

• Patient must not develop disease progression while receiving PBS-subsidised treatment with this drug for this condition.

Treatment criteria:

• Must be treated by a medical practitioner; OR

• Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.